Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

For those seeking retail therapy in a luxury shopping destination, Walthamstow high street probably isn’t top of the list ...

Webb took on several high-profile public roles in Hong Kong to champion the interest of shareholders and investors, including ...

Operator: Good day, and welcome to the Aethlon Medical Third Quarter Fiscal 2025 Earnings and Corporate Update Call. All ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...

Investment analysts at Wedbush issued their FY2029 earnings per share estimates for Voyager Therapeutics in a report released on Tuesday, February 11th. Wedbush analyst Y. Zhong expects that the ...

PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary T-cell(*1) expansion culture ...

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and complex class of genetic ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.